World's First Dual-Target ADC: Hengrui's FH-006 Advances Toward Lung Squamous Cell Carcinoma
May 18, 2026 17:41
CST Updated
May 19, 10:33
Hengrui Pharma
Innovative and High-Quality Pharmaceutical Developer
Innovative and High-Quality Pharmaceutical Developer